PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Cancer Res. Author manuscript; available in PMC 2010 December 1.
Published in final edited form as:
PMCID: PMC2789198
NIHMSID: NIHMS151080

Hypoxia regulates Insulin Receptor Substrate-2 expression to promote breast carcinoma cell survival and invasion

Abstract

Insulin Receptor Substrate-2 (IRS-2) belongs to the IRS family of adaptor proteins that function as signaling intermediates for growth factor, cytokine and integrin receptors, many of which have been implicated in cancer. Although the IRS proteins share significant homology, distinct functions have been attributed to each family member in both normal and tumor cells. In cancer, IRS-2 is positively associated with aggressive tumor behavior. In the current study, we demonstrate that IRS-2 expression, but not IRS-1 expression, is positively regulated by hypoxia, which selects for tumor cells with increased metastatic potential. We identify IRS-2 as a novel hypoxia responsive gene and establish that IRS-2 gene transcription increases in a HIF-dependent manner in hypoxic environments. IRS-2 is active to mediate IGF-1-dependent signals in hypoxia, and enhanced activation of Akt in hypoxia is dependent upon IRS-2 expression. Functionally, the elevated expression of IRS-2 facilitates breast carcinoma cell survival and invasion in hypoxia. Collectively, our results reveal a novel mechanism by which IRS-2 contributes to the aggressive behavior of hypoxic tumor cells.

Keywords: IRS-2, hypoxia, HIF, survival, invasion, breast cancer

Introduction

Insulin Receptor Substrate-2 (IRS-2) belongs to the IRS family of cytoplasmic adaptor proteins that function as signaling intermediates for activated cell surface receptors. The IRS proteins are immediate downstream effectors of the insulin-like growth factor-1 (IGF-1) and insulin receptors, several cytokine receptors, prolactin, growth hormone (GH) and vascular endothelial growth factor (VEGF) receptors, and members of the integrin receptor family (1). The IRS proteins act as scaffold proteins to recruit signaling molecules to the receptors to regulate intracellular signaling cascades (2). Although IRS-1 and IRS-2 share significant homology and both have been implicated in tumorigenesis, distinct functions for these adaptor proteins in cancer progression have been identified (1, 3). In this regard, IRS-2 is positively associated with aggressive tumor behavior. In MMTV-PyV-MT mice, mammary tumor metastasis is significantly diminished in the absence of Irs-2, and Irs-2 activation is enhanced in Irs-1-deficient tumors that are highly metastatic (4, 5). Similarly, Irs-2 expression is elevated in tumors that arise in PTEN-/+ mice, and deletion of Irs-2 suppresses tumor growth and progression to invasive disease (6).

Mechanistic experiments aimed at understanding how IRS-2 contributes to tumor progression have revealed a role for this adaptor protein in regulating cell invasion and survival. PyV-MT-derived mammary tumor cells that lack Irs-2 expression are less invasive and more sensitive to apoptosis induced by serum deprivation than are their wild type counterparts (5). IGF-1 predominantly induces IRS-2 phosphorylation in MDA-MB-231 human breast carcinoma cells selected for metastatic behavior in vivo (7). Introduction of an IRS-2 antisense mRNA into these metastatic cells results in decreased IGF-1-induced cell motility and anchorage-independent growth (7). Similarly, expression of IRS-2 in T47D breast carcinoma cells results in increased cell motility in response to IGF-1 stimulation (8). One mechanism by which IRS-2 promotes mammary tumor cell invasion is through the regulation of GLUT-1 localization to the cell surface to increase glucose uptake and enhance aerobic glycolysis (9). Tumor cells depend more upon glycolysis than oxidative phosphorylation to generate ATP and studies have shown that it provides tumor cells with a selective advantage in their ability to progress towards invasive and metastatic disease (10, 11)

Rapidly growing tumors develop areas of low oxygen tension, or hypoxia, when their growth outpaces the development of new blood vessels (12). Tumor cells that can develop a metabolic self-sufficiency through anaerobic glycolysis can survive in stressful environments that lack oxygen and other essential nutrients for energy production (13). In addition, hypoxia upregulates signaling pathways that facilitate invasion and survival (14, 15). Therefore, exposure of tumor cells to hypoxia creates a selection for cells with a more aggressive, invasive behavior (16, 17). To conserve energy in hypoxic conditions, overall gene expression is suppressed and primarily genes that are essential for low-oxygen/nutrient adaptation are expressed (18). Specifically, genes that are upregulated in response to hypoxia are involved in angiogenesis, DNA damage responses, glycolysis and survival (15). Upregulation of these genes in response to hypoxia ultimately leads to increased metastatic potential (15).

Given that IRS-2 has been implicated in promoting both tumor cell survival and invasion, and regulating tumor cell glycolysis, we sought to determine if IRS-2 expression is regulated by hypoxia, and if this adaptor protein contributes to breast carcinoma cell behavior in hypoxic microenvironments. In this study, we report that IRS-2 expression is increased upon exposure to hypoxia in breast carcinoma cells. The elevated expression of IRS-2 in response to hypoxia facilitates breast carcinoma cell survival and invasion.

Materials and Methods

Cell lines and hypoxia treatment

Mouse mammary tumor cell lines were isolated from PyV-MT-derived wild-type (WT) and Irs-2-/- tumors as described previously (5). MDA-MB-231 human breast carcinoma cells were obtained from ATCC. SUM159 and SUM149 human breast carcinoma cells were a gift from Dr. A. Mercurio (UMass Medical School).

For hypoxia exposure, cells were maintained at a constant gas mixture of 0.5% oxygen, 94.5% nitrogen and 5% carbon dioxide in an InVivo2 Hypoxia Workstation (Ruskinn Technology Ltd) for periods of time indicated in each Figure Legend.

Cycloheximide and Actinomycin-D treatments

Cells were incubated in normoxia or hypoxia for 16 hours and then cycloheximide (20ug/ml) (Sigma) or Actinomycin-D (10uM) (Sigma) were added to the cell culture medium for 1, 3, or 6 hours of incubation. Cells were also pretreated with Actinomycin-D (10uM) or DMSO for 30 minutes in normoxia before being transferred to hypoxia.

Luciferase assays

The human 1 Kb IRS-2 promoter-luciferase expression plasmid was a gift from Dr. J. Goldstein (UT Southwestern Medical Center) (19). The human 2.3 Kb IRS-2 promoter luciferase plasmid was a gift from Dr. A. Lee (Baylor College of Medicine) (20, 21). 0.6 Kb (-732 to -116) and 0.3 Kb (-428 to -116) IRS-2 promoter plasmids were generated by serial SmaI digestion of the 1 Kb IRS-2 promoter.

Cells were plated in triplicate wells of a 24-well plate and co-transfected with the promoter-luciferase plasmids (0.25 ug) and a pRL-CMV renilla luciferase plasmid (0.25 ug) (Promega). After an overnight incubation, duplicate plates were incubated either in hypoxia or normoxia for 24 hours. Cells were assayed for firefly and renilla luciferase activity using the Dual-Glo Luciferase Assay System (Promega).

RNAi-mediated suppression of gene expression

HIF1α and HIF2α smart pool siRNAs (Dharmacon) were transfected using Oligofectamine reagent (Invitrogen). Lentiviral vectors containing murine Irs-2 small hairpin RNAs (shRNA) were a gift from Dr. B. Lewis (UMass Medical School). Lentiviral vectors containing human IRS-2 and GFP small hairpin RNAs were obtained from Open Biosystems (Huntsville, AL).

RNA extraction and real-time quantitative PCR (RQ-PCR)

mRNA was extracted from cells using the RNeasy kit (Qiagen), treated with DNaseI (Invitrogen), and converted to cDNA using SuperscriptII® Reverse Transcriptase (Invitrogen). Gene expression was quantified using Syber Green RT-PCR master mix reagents (Applied Biosystems). The Delta Ct method was used to quantify the relative expression of each gene. IRS expression was normalized to either murine GAPDH or human Actin.

Immunoprecipitation and immunoblotting

IRS-2 immunoprecipitations and immunoblots were performed as described previously (5) using the following antibodies: IRS-2 (immunoblot, EMD Biosciences, Inc.; immunoprecipitation, Bethyl Labs); phosphotyrosine (PY99; Santa Cruz Biotechnology); p85 (gift from Dr. A. Toker, Harvard Medical School); IRS-1 (Bethyl Labs); tubulin (Sigma). All other antibodies were purchased from Cell Signaling Technology, Inc. Band intensities were quantified by densitometry using LabWorks Analysis Software (UVP, Inc.).

Apoptosis assays

Cells were plated at equal densities and allowed to adhere to plates in normoxia for 24 hours before being transferred to hypoxia for an additional 24 hours. For apoptosis assays with SUM159 cells, the culture medium was replaced with serum-free RPMI 1640 (GIBCO®) supplemented with 1g/L glucose prior to their transfer to hypoxia. Cells were analyzed using the Annexin V-PE Apoptosis Detection Kit (BD Pharmingen™).

Invasion assays

Cells were incubated in hypoxia for 16 hours prior to the invasion assay and then maintained in the hypoxia chamber during assay preparation. Invasion assays were performed as described previously (9).

Statistics

All data are represented as an average +/- standard error. All statistical analyses were performed using the unpaired Student's t-test.

Results

IRS-2 expression increases in response to hypoxia

To determine if IRS-2 expression is regulated by hypoxia, MDA-MB-231 breast carcinoma cells were incubated for increasing periods of time in hypoxic (0.5% oxygen) conditions. When compared with the level of IRS-2 expression in cells maintained in normoxia (0 hours), both IRS-2 protein and mRNA expression increased significantly in response to hypoxia (Figs. 1A and 1B). The induction of IRS-2 mRNA occurred within 8 hours of exposure to hypoxia, with maximal levels observed after 16-24 hours. IRS-1 mRNA expression did not increase in response to hypoxia over the same time course (Fig. 1B). However, IRS-1 protein expression decreased after 16 hrs in hypoxia, a result that is consistent with a previous report that IRS-1 can be degraded through a caspase-mediated cleavage in response to hypoxia (22). A modest upregulation of IRS-2 protein in the absence of an mRNA increase was sometimes observed in response to acute hypoxia (2 hours) (Fig. 1A). This increase is likely due to increased IRS-2 protein stability because pre-treatment of cells with cycloheximide did not prevent this early IRS-2 protein increase (data not shown).

Figure 1
Hypoxia induces IRS-2 expression

To determine if upregulation of IRS-2 expression is a common response of breast carcinoma cells to hypoxic conditions, IRS-2 expression was evaluated in additional cell lines. As was observed for MDA-MB-231 cells, IRS-2 mRNA and protein expression increased after 16 hrs in hypoxia in SUM159 and SUM149 human breast carcinoma cells, and also in a mouse mammary tumor cell line (PyV-MT:WT) (Figs. 1C and 1D) (5). IRS-1 protein and mRNA levels either remained unchanged (human) or decreased (mouse) in response to hypoxia in these additional cell lines (Fig. 1C, data not shown).

Hypoxia regulates IRS-2 transcription

To examine the mechanism by which IRS-2 expression is enhanced by hypoxia, we compared IRS-2 protein and mRNA stability under normoxic and hypoxic conditions in murine PyV-MT:WT and human MDA-MB-231 cells. Cells were incubated for 16 hours in hypoxia and then treated with either cycloheximide (CH) or Actinomycin D (ActD) for additional time periods to inhibit protein translation or mRNA transcription, respectively. IRS-1 and IRS-2 protein expression decreased in both cell lines after addition of CH in both normoxic and hypoxic conditions (Fig. 2A). Densitometric analysis revealed that IRS-2 protein is slightly less stable in hypoxia when compared with normoxia (Fig. 2B). The decreased gel mobility observed for both IRS-1 and IRS-2 after treatment with CH is most likely due to increased ubiquitination, as it has been previously shown that the IRS proteins can be degraded through ubiquitin-dependent proteasomal degradation (23, 24). IRS-2 mRNA stability was similar in hypoxia and normoxia for both murine PyV-MT:WT and human MDA-MB-231 cell lines (Fig. 2C).

Figure 2
IRS-2 protein and mRNA stability are not increased by hypoxia

Next, we sought to determine if IRS-2 mRNA expression is regulated by hypoxia at the level of gene transcription. MDA-MB-231 cells were pretreated with ActD for 30 minutes prior to hypoxic exposure to block de novo gene transcription. Cells were incubated for 16 hours in hypoxia in the continued presence of ActD or vehicle (DMSO), or left untreated. ActD pre-incubation inhibited the upregulation of IRS-2 expression in response to hypoxia (Fig.3A). To investigate further the hypoxic regulation of IRS-2 transcription, MDA-MB-231 cells were transiently transfected with a pGL3-luciferase plasmid containing 2.3 Kb of the human IRS-2 promoter (20). A 2.5 fold induction of luciferase activity was observed in hypoxia for the IRS-2 promoter, which mimics the fold change in endogenous IRS-2 mRNA expression in MDA-MB-231 cells (Fig. 3B). To identify a hypoxia responsive region of the IRS-2 promoter, pGL3 plasmids containing progressive deletions of the IRS-2 promoter were evaluated for luciferase activity in hypoxia. A decrease in normoxic promotor activity was observed upon progressive deletion of the IRS-2 promoter, with a total loss of activity between -732 and -428 of the promoter. An insulin response element (IRE) that is important for the regulation of basal IRS-2 expression has been identified previously in this region (19). However, the IRS-2 promoters that retain luciferase activity in normoxia (1 Kb and 0.6 Kb) also exhibited a 2.5 fold upregulation in activity in response to hypoxia (Fig. 3B). Taken together, our data establish that transcription is required for hypoxic regulation of IRS-2 expression and identify a hypoxia-responsive region between −732 and −428 of the IRS-2 promoter.

Figure 3
Hypoxia regulates IRS-2 transcription

HIF-1 and HIF-2 are required for the regulation of IRS-2 transcription in response to hypoxia

The HIF family of transcription factors are the major regulators of hypoxia-induced transcription (25-27). To determine if HIF-1 or HIF-2 play a role in regulating IRS-2 expression in response to hypoxia, an siRNA targeting approach was used to transiently suppress HIF-1α or HIF-2α expression (Fig. 3C). Knockdown of HIF-1α or HIF-2α alone did not significantly inhibit IRS-2 protein or mRNA expression in hypoxia. However, simultaneous knockdown of both HIF-1α and HIF-2α prevented IRS-2 protein and mRNA upregulation in response to hypoxia (Fig. 3D).

IRS-2 is competent for signaling in hypoxic environments

IRS-2 is phosphorylated on multiple tyrosine and serine residues in response to different stimuli, which results in a mobility shift on SDS-PAGE gels (2). We observed that IRS-2 mobility increases after exposure to hypoxia for more than 12 hours, which could reflect a decrease in tyrosine phosphorylation and a corresponding decrease in IRS-2 signaling. To determine if IRS-2 retains functional activity in hypoxia, we examined the signaling potential of IRS-2 in hypoxic cells. IRS-2 tyrosine phosphorylation levels and binding to the regulatory subunit of PI3K (p85) were compared in SUM159 cells that were incubated for 15 hrs in normoxia or hypoxia in the presence or absence of IGF-1 (50 ng/ml), or stimulated with IGF-1 for 15 minutes at the end of the 15-hour incubation. In normoxia, IRS-2 tyrosyl-phosphorylation increased in response to both acute and long-term IGF-1 stimulation, and PI3K recruitment increased in parallel (Fig. 4A). In hypoxia, IRS-2 phosphorylation levels and association with PI3K were elevated 2.7-fold in the absence of exogenous IGF-1 stimulation when compared with cells maintained in normoxia, and both tyrosine phosphorylation and PI3K interactions were increased further in response to acute IGF-1 stimulation (15 min) (Fig. 4A). Long-term IGF-1 stimulation under hypoxic conditions resulted in decreased IRS-2 expression, tyrosine-phosphorylation and association with p85 (Fig.4A), most likely due to the activation of a negative feedback mechanism in response to prolonged activation of this pathway (23). Therefore, IRS-2 is functionally active and capable of signaling in hypoxic cells.

Figure 4
IRS-2 signaling in hypoxia

To investigate further how IRS-2 contributes to the hypoxic tumor response, activation of intracellular signaling pathways in PyV-MT:WT and PyV-MT:Irs-2-/- mammary tumor cell lines were examined in either normoxia or hypoxia. MAPK activation was induced by hypoxia in both cell lines and there was a modest increase in activation in the presence of IGF-1 (Fig.4B). Activation of Akt was increased 16-fold in WT cells in response to hypoxia, and activation was enhanced further in response to IGF-1 stimulation (Fig. 4B). However, Akt activation did not increase in hypoxia in the absence of IRS-2 (Fig. 4B).

IRS-2 promotes tumor cell viability in hypoxia

Genes that allow cells to adapt to low oxygen conditions are upregulated in hypoxia (15, 18). To determine if enhanced IRS-2 expression contributes to cell survival in hypoxia, PyV-MT:WT and PyV-MT:Irs-2-/- mammary tumor cells were incubated in hypoxia or normoxia for 24 hours in complete culture medium. PyV-MT:Irs-2-/- cells were significantly more sensitive to hypoxia-induced apoptosis than PyV-MT:WT cells (Fig.5A). To confirm a role for IRS-2 in the survival of mammary tumor cells in hypoxic environments, IRS-2 expression was suppressed by shRNA in PyV-MT:WT cells. Cells expressing IRS-2-specific shRNA were more apoptotic in hypoxia when compared with cells expressing vector alone or parental PyV-MT:WT cells (Fig.5B). A similar impact of IRS-2 on survival in hypoxia was observed for the human SUM159 cell line. Cells expressing two independent IRS-2 shRNA targeting sequences exhibited a significant increase in hypoxia-induced apoptosis when compared with parental or GFP shRNA expressing cells (Fig.5C).

Figure 5
IRS-2 promotes cell survival in hypoxia

IRS-2 promotes tumor cell invasion in hypoxia

Stable shRNA-mediated knockdown of IRS-2 in MDA-MB-231 cells did not sensitize these cells to hypoxia-induced apoptosis (data not shown). MDA-MB-231 cells are likely resistant to apoptosis in response to IRS-2 suppression because they express mutated Ras, which can directly activate survival signaling pathways, bypassing the need for IRS-2 (28). However, suppression of IRS-2 expression impaired significantly the ability of this highly metastatic cell line to invade in hypoxic conditions. Hypoxic cells with decreased IRS-2 levels were over 50% less invasive than parental or control GFP shRNA expressing cells (Fig. 6). In contrast, suppression of IRS-2 did not inhibit the invasion of PyV-MT:WT and SUM159 cells in hypoxia (data not shown). Taken together with the differential impact of IRS-2 on the survival of breast carcinoma cells, our data support that IRS-2 promotes either breast carcinoma survival or invasion in hypoxia in a cell type-dependent manner, which is likely to reflect the heterogeneity of signaling pathway activity in tumor cells.

Figure 6
IRS-2 promotes invasion in hypoxia

Discussion

In this study, we identify IRS-2 as a hypoxia-responsive gene that contributes to breast carcinoma cell survival and invasion in hypoxic environments. Exposure of breast carcinoma cells to hypoxia increases IRS-2 expression, but not IRS-1 expression, at the level of gene transcription. Either HIF-1 or HIF-2 is required for this hypoxia-dependent increase in IRS-2 expression. IRS-2 is phosphorylated on tyrosine residues and recruits PI3K in response to IGF-1 stimulation in hypoxia, indicating that IRS-2 is functionally active to mediate signaling in low oxygen conditions. In this regard, activation of Akt in response to hypoxia is dependent upon IRS-2 expression. Functionally, IRS-2 can protect cells from apoptosis and promote invasion in hypoxic environments. Collectively, our results provide a novel mechanism by which IRS-2 contributes to the aggressive behavior and metastasis of hypoxic tumor cells.

IRS-1 and IRS-2 expression are differentially regulated by hypoxia in breast carcinoma cells, a finding that adds to a growing body of evidence that these homologous adaptor proteins are not functionally redundant. IGF-1-dependent signaling through IRS-1 or IRS-2 in human breast carcinoma cells stimulates proliferation or migration/invasion, respectively (8). IRS-2, but not IRS-1, has been implicated in metabolic regulation in tumor cells, through the regulation of glycolysis (9). In vivo, mammary tumors that lack Irs-2 expression are significantly impaired in their ability to metastasize, and Irs-1 cannot compensate for this function (5). In fact, in the absence of Irs-1 expression, Irs-2 expression and signaling increase in cell lines in culture and in tumors, and metastasis is enhanced (4). Taken together, these findings infer that the balance of IRS-1 and IRS-2 expression can significantly impact tumor cell function and progression. Shifting the IRS balance in favor of IRS-2 would promote metabolic independence, invasive ability and survival, factors that contribute to the metastatic potential of a tumor. The fact that hypoxia concurrently suppresses IRS-1 expression while upregulating IRS-2 expression reveals a novel endogenous mechanism by which this balance is altered to favor tumor progression.

The regulation of IRS-2 gene expression by hypoxia implicates IRS-2 in the adaptation of tumor cells to hypoxia and reveals a novel mechanism by which hypoxic cells acquire a more aggressive behavior after exposure to low oxygen conditions. Hypoxia occurs in areas of tumors that are poorly vascularized, which results in decreased oxygen delivery to the tumor cells (16). Overall, gene expression is suppressed in hypoxia as a mechanism to conserve energy in this stresssful microenvironment, which is often lacking in nutrient availability as well (15). In general, the genes that are expressed in hypoxic environments are essential for tumor cells to survive in, and ultimately adapt to, low oxygen conditions. For example, genes that regulate anaerobic glycolysis are coordinately expressed in hypoxia to facilitate energy production when oxidative phosphorylation is inhibited by insufficient oxygenation (15, 25). Genes such as VEGF are also upregulated to increase angiogenesis and restore normoxic conditions (29). Chronic exposure to hypoxia creates a selection for cells with a tolerance for hypoxia and these cells become more invasive and metastatic (16, 17). The impact of this selective pressure is highlighted by recent studies revealing that anti-angiogenic therapy alone may provide only short term benefit for many cancer patients because the disruption of blood vessels leads to increased hypoxia, and patients will go on to develop metastatic disease (30, 31). These studies underscore the importance of understanding how tumor cells maintain their viability in hypoxia. Our current findings that IRS-2 contributes to breast carcinoma cell survival in hypoxia, along with our previous demonstrations that IRS-2 regulates aerobic glycolysis and positively contributes to mammary tumor metastasis, identify this adaptor protein as a key mediator of signals that influence tumor cell responses to hypoxia.

Our data reveal that one mechanism by which IRS-2 contributes to the hypoxic tumor response is by sustaining activation of Akt in hypoxia. In our previous in vivo studies, Akt signaling was upregulated in PyV-MT:Irs-1-/- tumors that have enhanced Irs-2 expression and association with PI3K, providing evidence that our in vitro findings linking IRS-2 with Akt activation are recapitulated in tumors (4). A number of studies have implicated Akt signaling in positively regulating tumor cell survival in hypoxia and several mechanisms for its action have been proposed (32). Akt negatively regulates the function of pro-apoptotic downstream effectors including the FOXO transcription factors and the pro-apoptotic protein Bad (33). IRS-2 regulates FOXO function through Akt in mouse embryo fibroblasts, and this regulatory pathway has been proposed to control nutrient homeostasis (34). Viability and growth are also influenced by the Akt-dependent regulation of genes that control energy production through the switch from oxidative phosphorylation to anaerobic glycolysis for ATP generation (35). Akt signaling can also enhance the expression of HIF-1α to amplify the expression of HIF target genes (36, 37). In this regard, SUM149 cells, which lack PTEN and have elevated Akt activity, exhibited the greatest induction of IRS-2 expression in hypoxia (38). As mentioned previously, tumors that arise in PTEN+/- mice also have elevated IRS-2 expression (6). These findings raise the possibility that in tumor cells with PI3K pathway mutations, hypoxia provides a second “positive hit” by upregulating IRS-2 expression to counterbalance negative feedback regulation of IRS-2, and by doing so enhancing downstream PI3K signaling to promote tumor progression.

Hypoxic regulation of IRS-2 expression requires the function of either HIF-1 or HIF-2. The HIFs are major regulators of hypoxia-responsive gene transcription and each factor consists of two subunits, HIF-α and HIF-β/ARNT (39). HIF-1α and HIF-2α subunits are highly homologous, and both contain basic helix-loop-helix (bHLH), Per/ARNT/Sim (PAS), and oxygen-dependent degradation (ODD) domains (39). In low oxygen conditions, the HIF-α subunit is stabilized and it interacts with HIF-β to form the active HIF transcription factor, which binds to HRE sequences in target genes (40). HIF-1 and HIF-2 can regulate both unique and common target genes (41, 42). Suppression of both HIF-1α and HIF-2α was required to prevent hypoxia-dependent upregulation, indicating that IRS-2 is a common target gene for HIF-1 and HIF-2. However, given the lack of a canonical HRE in the hypoxia responsive region of the promoter that we identified and the delayed timing of the increase in IRS-2 expression in response to hypoxia, additional factors are likely to contribute to the regulation of IRS-2 expression. A number of transcription factors have been identified that stimulate gene expression in response to hypoxia, and these factors either act in cooperation with HIF, or are regulated by HIF, to alter hypoxic gene expression (43). Importantly, some of these transcription factors have been previously implicated in the regulation of IRS-2 gene expression including AP-1, the forkhead transcription factors FOXO1 and FOXO3a, and CREB (21, 44, 45).

In summary, we have established a novel mechanism by which hypoxia selects for aggressive tumor behavior and promotes metastatic disease. The identification of IRS-2 as a hypoxia-responsive gene that regulates signaling pathways important for tumor cell survival and invasion in hypoxic environments opens a new avenue for investigation into how this pathway could be manipulated for therapeutic benefit.

Acknowledgments

This work was supported by NIH grant CA090583 (LMS) and Department of Defense Breast Cancer Predoctoral Fellowship BC073053 (KM).

References

1. Gibson SL, Ma Z, Shaw LM. Divergent roles for IRS-1 and IRS-2 in breast cancer metastasis. Cell Cycle. 2007;6:631–7. [PubMed]
2. White MF. IRS proteins and the common path to diabetes. Am J Physiol Endocrinol Metab. 2002;283:E413–22. [PubMed]
3. Dearth RK, Cui X, Kim HJ, et al. Mammary tumorigenesis and metastasis caused by overexpression of insulin receptor substrate 1 (IRS-1) or IRS-2. Mol Cell Biol. 2006;26:9302–14. [PMC free article] [PubMed]
4. Ma Z, Gibson SL, Byrne MA, Zhang J, White MF, Shaw LM. Suppression of insulin receptor substrate 1 (IRS-1) promotes mammary tumor metastasis. Mol Cell Biol. 2006;26:9338–51. [PMC free article] [PubMed]
5. Nagle JA, Ma Z, Byrne MA, White MF, Shaw LM. Involvement of insulin receptor substrate 2 in mammary tumor metastasis. Mol Cell Biol. 2004;24:9726–35. [PMC free article] [PubMed]
6. Szabolcs M, Keniry M, Simpson L, et al. Irs2 inactivation suppresses tumor progression in Pten+/- mice. Am J Pathol. 2009;174:276–86. [PubMed]
7. Jackson JG, Zhang X, Yoneda T, Yee D. Regulation of breast cancer cell motility by insulin receptor substrate-2 (IRS-2) in metastatic variants of human breast cancer cell lines. Oncogene. 2001;20:7318–25. [PubMed]
8. Byron SA, Horwitz KB, Richer JK, Lange CA, Zhang X, Yee D. Insulin receptor substrates mediate distinct biological responses to insulin-like growth factor receptor activation in breast cancer cells. Br J Cancer. 2006;95:1220–8. [PMC free article] [PubMed]
9. Pankratz SL, Tan EY, Fine Y, Mercurio AM, Shaw LM. Insulin receptor substrate-2 regulates aerobic glycolysis in mouse mammary tumor cells via glucose transporter 1. J Biol Chem. 2009;284:2031–7. [PubMed]
10. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004;4:891–9. [PubMed]
11. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008;7:11–20. [PubMed]
12. Pouyssegur J, Dayan F, Mazure NM. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature. 2006;441:437–43. [PubMed]
13. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003;3:721–32. [PubMed]
14. Wang X, Martindale JL, Liu Y, Holbrook NJ. The cellular response to oxidative stress: influences of mitogen-activated protein kinase signalling pathways on cell survival. Biochem J. 1998;333:291–300. [PubMed]
15. Bertout JA, Patel SA, Simon MC. The impact of O2 availability on human cancer. Nat Rev Cancer. 2008;8:967–75. [PMC free article] [PubMed]
16. Axelson H, Fredlund E, Ovenberger M, Landberg G, Pahlman S. Hypoxia-induced dedifferentiation of tumor cells--a mechanism behind heterogeneity and aggressiveness of solid tumors. Semin Cell Dev Biol. 2005;16:554–63. [PubMed]
17. Liao D, Corle C, Seagroves TN, Johnson RS. Hypoxia-inducible factor-1alpha is a key regulator of metastasis in a transgenic model of cancer initiation and progression. Cancer Res. 2007;67:563–72. [PubMed]
18. Wouters BG, Koritzinsky M. Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer. 2008;8:851–64. [PubMed]
19. Zhang J, Ou J, Bashmakov Y, Horton JD, Brown MS, Goldstein JL. Insulin inhibits transcription of IRS-2 gene in rat liver through an insulin response element (IRE) that resembles IREs of other insulin-repressed genes. Proc Natl Acad Sci U S A. 2001;98:3756–61. [PubMed]
20. Iwamoto K, Mori H, Okazawa H, Hashiramoto M, Kasuga M. Identification of a single nucleotide polymorphism showing no insulin-mediated suppression of the promoter activity in the human insulin receptor substrate 2 gene. Diabetologia. 2002;45:1182–95. [PubMed]
21. Cui X, Kim HJ, Kuiatse I, Kim H, Brown PH, Lee AV. Epidermal Growth Factor Induces Insulin Receptor Substrate-2 in Breast Cancer Cells via c-Jun NH2-Terminal Kinase/Activator Protein-1 Signaling to Regulate Cell Migration. Cancer Res. 2006;66:5304–13. [PubMed]
22. Kang SG, Brown AL, Chung JH. Oxygen tension regulates the stability of insulin receptor substrate-1 (IRS-1) through caspase-mediated cleavage. J Biol Chem. 2007;282:6090–7. [PubMed]
23. Rui L, Fisher TL, Thomas J, White MF. Regulation of insulin/insulin-like growth factor-1 signaling by proteasome-mediated degradation of insulin receptor substrate-2. J Biol Chem. 2001;276:40362–7. [PubMed]
24. Xu X, Sarikas A, Dias-Santagata DC, et al. The CUL7 E3 ubiquitin ligase targets insulin receptor substrate 1 for ubiquitin-dependent degradation. Mol Cell. 2008;30:403–14. [PMC free article] [PubMed]
25. Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol. 1992;12:5447–54. [PMC free article] [PubMed]
26. Ema M, Taya S, Yokotani N, Sogawa K, Matsuda Y, Fujii-Kuriyama Y. A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development. Proc Natl Acad Sci U S A. 1997;94:4273–8. [PubMed]
27. Greijer AE, van der Groep P, Kemming D, et al. Up-regulation of gene expression by hypoxia is mediated predominantly by hypoxia-inducible factor 1 (HIF-1) J Pathol. 2005;206:291–304. [PubMed]
28. Toulany M, Dittmann K, Baumann M, Rodemann HP. Radiosensitization of Ras-mutated human tumor cells in vitro by the specific EGF receptor antagonist BIBX1382BS. Radiother Oncol. 2005;74:117–29. [PubMed]
29. Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol. 1996;16:4604–13. [PMC free article] [PubMed]
30. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009;15:232–9. [PubMed]
31. Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009;15:220–31. [PMC free article] [PubMed]
32. Alvarez-Tejado M, Naranjo-Suarez S, Jimenez C, Carrera AC, Landazuri MO, del Peso L. Hypoxia induces the activation of the phosphatidylinositol 3-kinase/Akt cell survival pathway in PC12 cells: protective role in apoptosis. J Biol Chem. 2001;276:22368–74. [PubMed]
33. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev. 1999;13:2905–27. [PubMed]
34. Guo S, Dunn SL, White MF. The reciprocal stability of FOXO1 and IRS2 creates a regulatory circuit that controls insulin signaling. Mol Endocrinol. 2006;20:3389–99. [PubMed]
35. Robey RB, Hay N. Is Akt the “Warburg kinase”?-Akt-energy metabolism interactions and oncogenesis. Semin Cancer Biol. 2009;19:25–31. [PMC free article] [PubMed]
36. Zundel W, Schindler C, Haas-Kogan D, et al. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev. 2000;14:391–6. [PubMed]
37. Mottet D, Dumont V, Deccache Y, et al. Regulation of hypoxia-inducible factor-1alpha protein level during hypoxic conditions by the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3beta pathway in HepG2 cells. J Biol Chem. 2003;278:31277–85. [PubMed]
38. Oda K, Okada J, Timmerman L, et al. PIK3CA cooperates with other phosphatidylinositol 3′-kinase pathway mutations to effect oncogenic transformation. Cancer Res. 2008;68:8127–36. [PubMed]
39. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A. 1995;92:5510–4. [PubMed]
40. Semenza GL, Jiang BH, Leung SW, et al. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem. 1996;271:32529–37. [PubMed]
41. Hu CJ, Wang LY, Chodosh LA, Keith B, Simon MC. Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol Cell Biol. 2003;23:9361–74. [PMC free article] [PubMed]
42. Wang V, Davis DA, Haque M, Huang LE, Yarchoan R. Differential gene up-regulation by hypoxia-inducible factor-1alpha and hypoxia-inducible factor-2alpha in HEK293T cells. Cancer Res. 2005;65:3299–306. [PubMed]
43. Kenneth NS, Rocha S. Regulation of gene expression by hypoxia. Biochem J. 2008;414:19–29. [PubMed]
44. Jhala US, Canettieri G, Screaton RA, et al. cAMP promotes pancreatic beta-cell survival via CREB-mediated induction of IRS2. Genes Dev. 2003;17:1575–80. [PubMed]
45. Ide T, Shimano H, Yahagi N, et al. SREBPs suppress IRS-2-mediated insulin signalling in the liver. Nat Cell Biol. 2004;6:351–7. [PubMed]